Alpha2-Plasmin Inhibitor Deficiency Questions & Answers

1. Singh S, Saleem S, Reed GL. Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease. Front Cardiovasc Med. 2020. 7:608899. [QxMD MEDLINE Link]. [Full Text].

2. Abdul S, Leebeek FW, Rijken DC, Uitte de Willige S. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences. Blood. 2016 Feb 4. 127 (5):538-45. [QxMD MEDLINE Link]. [Full Text].

3. Hanss MM, Farcis M, Ffrench PO, de Mazancourt P, Dechavanne M. A splicing donor site point mutation in intron 6 of the plasmin inhibitor (alpha2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency. Blood Coagul Fibrinolysis. 2003 Jan. 14(1):107-11. [QxMD MEDLINE Link].

4. Maino A, Garagiola I, Artoni A, Al-Humood S, Peyvandi F. A novel mutation of alpha2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. Haemophilia. 2008 Jan. 14(1):166. [QxMD MEDLINE Link].

5. Akay M, Zaidi A, Vaidya S, Sivapalaratnam S, Theodoulou A, Platton S, et al. A novel variant causing α2 antiplasmin deficiency: case report and experience in a UK centre. Br J Haematol. 2019 Oct. 187 (2):e42-e44. [QxMD MEDLINE Link]. [Full Text].

6. Koie K, Kamiya T, Ogata K, Takamatsu J. Alpha2-plasmin-inhibitor deficiency (Miyasato disease). Lancet. 1978 Dec 23-30. 2(8104-5):1334-6. [QxMD MEDLINE Link].

7. Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood. 1982 Jun. 59(6):1169-80. [QxMD MEDLINE Link]. [Full Text].

8. Bachmann F. Plasminogen-plasmin enzyme system. Colman RW, Hirsh J, George JN, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 275-320.

9. Bachmann F. The fibrinolytic system and thrombolytic agents. Bachmann F, ed. Fibrinolytics and Antifibrinolytics. Berlin, Germany: Springer-Verlag; 2001. 3-15.

10. Francis CW, Marder VJ. Physiologic regulation and pathologic disorders of fibrinolysis. Colman RW, Hirsh J, George JN, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 975-1002.

11. Rijken DC, Abdul S, Malfliet JJ, Leebeek FW, Uitte de Willige S. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII. J Thromb Haemost. 2016 Jul. 14 (7):1453-61. [QxMD MEDLINE Link]. [Full Text].

12. Rijken DC, Uitte de Willige S. Inhibition of Fibrinolysis by Coagulation Factor XIII. Biomed Res Int. 2017. 2017:1209676. [QxMD MEDLINE Link]. [Full Text].

13. Bagoly Z, Baráth B, Orbán-Kálmándi R, Szegedi I, Bogáti R, Sarkady F, et al. Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients. Biomolecules. 2021 Feb 25. 11 (3):[QxMD MEDLINE Link]. [Full Text].

14. Castellino FJ, Ploplis VA. Plasminogen and streptokinase. Bachmann F, ed. Fibrinolytics and Antifibrinolytics. Berlin: Springer-Verlag; 2001. 26-56.

15. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood. 1999 Apr 1. 93(7):2274-81. [QxMD MEDLINE Link]. [Full Text].

16. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Biologicals. 2007 Oct. 35 (4):349-53. [QxMD MEDLINE Link].

17. Hedner U, Hirsh J, Marder VJ. Therapy with antifibrinolytic agents. Colman RW, Hirsh J, George JN, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 796-813.

18. Bachmann F. Disorders of fibrinolysis and use of antifibrinolytic agents. Beutler E, Lichtman MA, Coller BS, et al, eds. Williams Hematology. 6th ed. New York, NY: McGraw-Hill; 2001. 1829-40.

19. Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs. 1995 Jun. 49(6):954-83. [QxMD MEDLINE Link].

20. Octaplas, Pooled Plasma (Human), Solvent/Detergent Treated [package insert]. Paramus, NJ: Octapharma USA Inc. 2013. Available at [Full Text].

21. Liumbruno GM, Marano G, Grazzini G, Capuzzo E, Franchini M. Solvent/detergent-treated plasma: a tale of 30 years of experience. Expert Rev Hematol. 2015 Jun. 8 (3):367-74. [QxMD MEDLINE Link].

22. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008 May 29. 358(22):2319-31. [QxMD MEDLINE Link]. [Full Text].

23. Royston D, De Hert S, van der Linden J, Ouattara A, Zacharowski K. A special article following the relicence of aprotinin injection in Europe. Anaesth Crit Care Pain Med. 2017 Apr. 36 (2):97-102. [QxMD MEDLINE Link].

Olga Kozyreva, MD Attending Physician, Division of Hematology-Oncology, St Elizabeth's Medical Center; Assistant Professor, Tufts University School of Medicine

Disclosure: Nothing to disclose.

Samer A Bleibel, MD Staff Physician, Department of Internal Medicine, Wayne State University School of Medicine, St John's Hospital and Medical Centers

Samer A Bleibel, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Sarah K May, MD Consulting Staff, Department of Hematology-Oncology, Caritas Carney Hospital, Commonwealth Hematology-Oncology PC

Disclosure: Nothing to disclose.

Rajalaxmi McKenna, MD, FACP Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Jeanine M Walenga, PhD, MT(ASCP), FACA Professor, Departments of Thoracic and Cardiovascular Surgery and Pathology, Cardiovascular Institute, Loyola University Medical Center

Jeanine M Walenga, PhD, MT(ASCP), FACA is a member of the following medical societies: Academy of Clinical and Applied Thrombosis/Hemostasis, American Association for Clinical Chemistry, American College of Angiology, American Heart Association, American Medical Technologists, American Society for Clinical Pathology, American Society of Hematology, European and Mediterranean League Against Thrombotic Diseases, International Society for Applied Cardiovascular Biology, International Society on Thrombosis and Haemostasis, New York Academy of Sciences, Society for Thrombosis and Haemostasis Research

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Marcel E Conrad, MD Distinguished Professor of Medicine (Retired), University of South Alabama College of Medicine

Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, SWOG

Disclosure: Partner received none from No financial interests for none.

Perumal Thiagarajan, MD Professor, Department of Pathology and Medicine, Baylor College of Medicine; Director, Transfusion Medicine and Hematology Laboratory, Michael E DeBakey Veterans Affairs Medical Center

Perumal Thiagarajan, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society for Biochemistry and Molecular Biology, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Royal College of Physicians

Disclosure: Nothing to disclose.

S Gerald Sandler, MD, FCAP, FACP Professor Emeritus of Medicine and Pathology, Georgetown University School of Medicine

S Gerald Sandler, MD, FCAP, FACP is a member of the following medical societies: American Association of Blood Banks, College of American Pathologists, International Society of Blood Transfusion

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article